Sanofi (NASDAQ:SNY) Reaches New 1-Year Low Following Weak Earnings

Key Points

Error: Response status code does not indicate success: 429 (Too Many Requests).

Sanofi (NASDAQ:SNY - Get Free Report) shares reached a new 52-week low during trading on Thursday after the company announced weaker than expected quarterly earnings. The company traded as low as $44.73 and last traded at $46.05, with a volume of 2347885 shares. The stock had previously closed at $49.25.

The company reported $0.90 EPS for the quarter, missing the consensus estimate of $0.96 by ($0.06). The business had revenue of $11.34 billion for the quarter, compared to analysts' expectations of $9.91 billion. Sanofi had a net margin of 21.47% and a return on equity of 18.85%. The business's quarterly revenue was down 7.0% compared to the same quarter last year. During the same quarter last year, the company posted $1.73 earnings per share.

Wall Street Analyst Weigh In

Several equities analysts have recently commented on the company. Hsbc Global Res upgraded Sanofi to a "strong-buy" rating in a research note on Monday, April 28th. BNP Paribas assumed coverage on Sanofi in a research note on Tuesday, April 15th. They set an "outperform" rating and a $65.00 target price for the company. Morgan Stanley set a $56.00 target price on Sanofi in a research note on Monday, June 2nd. Wall Street Zen upgraded Sanofi from a "hold" rating to a "buy" rating in a research note on Saturday. Finally, Barclays restated an "overweight" rating on shares of Sanofi in a research note on Wednesday, July 2nd. Two equities research analysts have rated the stock with a hold rating, four have given a buy rating and three have issued a strong buy rating to the stock. According to data from MarketBeat, Sanofi currently has a consensus rating of "Buy" and an average price target of $62.00.

Hedge Funds Weigh In On Sanofi

Several large investors have recently added to or reduced their stakes in the company. Accent Capital Management LLC acquired a new stake in Sanofi in the first quarter worth $29,000. Eastern Bank increased its position in Sanofi by 121.0% in the first quarter. Eastern Bank now owns 548 shares of the company's stock worth $30,000 after buying an additional 300 shares during the period. Ameritas Advisory Services LLC acquired a new stake in Sanofi in the second quarter worth $28,000. Golden State Wealth Management LLC increased its position in Sanofi by 619.3% in the first quarter. Golden State Wealth Management LLC now owns 633 shares of the company's stock worth $35,000 after buying an additional 545 shares during the period. Finally, Banque Transatlantique SA acquired a new stake in Sanofi in the first quarter worth $33,000. 14.04% of the stock is currently owned by institutional investors.

Sanofi Price Performance

The company has a debt-to-equity ratio of 0.16, a current ratio of 1.37 and a quick ratio of 0.69. The company has a 50-day simple moving average of $49.10 and a two-hundred day simple moving average of $52.08. The stock has a market capitalization of $114.65 billion, a price-to-earnings ratio of 11.24, a price-to-earnings-growth ratio of 1.05 and a beta of 0.48.

About Sanofi

Sanofi, a healthcare company, engages in the research, development, manufacture, and marketing of therapeutic solutions in the United States, Europe, Canada, and internationally. It operates through Pharmaceuticals, Vaccines, and Consumer Healthcare segments. The company provides specialty care, such as DUPIXENT, neurology and immunology, rare diseases, oncology, and rare blood disorders; medicines for diabetes and cardiovascular diseases; and established prescription products.